{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+II+Bladder+Urothelial+Carcinoma", "query": { "condition": "Stage II Bladder Urothelial Carcinoma" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 161, "total_pages": 17, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Stage+II+Bladder+Urothelial+Carcinoma&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-10T05:46:02.056Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00088946", "title": "Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "Polyphenon E", "type": "DIETARY_SUPPLEMENT" }, { "name": "erlotinib hydrochloride", "type": "DRUG" }, { "name": "Erlotinib placebo", "type": "OTHER" }, { "name": "Polyphenon E", "type": "OTHER" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "DRUG", "OTHER" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2004-05", "completion_date": "2006-07", "has_results": false, "last_update_posted_date": "2020-07-31", "last_synced_at": "2026-06-10T05:46:02.056Z", "location_count": 5, "location_summary": "Phoenix, Arizona • Los Angeles, California • Santa Monica, California + 1 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00088946" }, { "nct_id": "NCT00981656", "title": "Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "cisplatin", "type": "DRUG" }, { "name": "5-fluorouracil", "type": "DRUG" }, { "name": "Mitomycin", "type": "DRUG" }, { "name": "Three-Dimensional Conformal Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Radiation Therapy Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 37, "start_date": "2009-11", "completion_date": "2023-08-15", "has_results": true, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-06-10T05:46:02.056Z", "location_count": 13, "location_summary": "Atlanta, Georgia • Baltimore, Maryland • Fall River, Massachusetts + 9 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Fall River", "state": "Massachusetts" }, { "city": "Lebanon", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT00981656" }, { "nct_id": "NCT00080795", "title": "Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Cancer", "Transitional Cell Cancer of the Renal Pelvis and Ureter", "Urethral Cancer" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "gemcitabine hydrochloride", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "conventional surgery", "type": "PROCEDURE" }, { "name": "neoadjuvant therapy", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 65, "start_date": "2001-07", "completion_date": "2006-05", "has_results": false, "last_update_posted_date": "2012-10-22", "last_synced_at": "2026-06-10T05:46:02.056Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00080795" }, { "nct_id": "NCT06630416", "title": "Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Bladder Urothelial Carcinoma", "Metastatic Malignant Solid Neoplasm", "Stage IV Bladder Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2024-11-27", "completion_date": "2030-05-10", "has_results": false, "last_update_posted_date": "2026-02-24", "last_synced_at": "2026-06-10T05:46:02.056Z", "location_count": 2, "location_summary": "Chicago, Illinois • Orland Park, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Orland Park", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06630416" }, { "nct_id": "NCT01663285", "title": "Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Urothelial Cancer", "Bladder Cancer" ], "interventions": [ { "name": "Neoadjuvant Cisplatin and Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2012-09", "completion_date": "2014-01", "has_results": true, "last_update_posted_date": "2015-12-03", "last_synced_at": "2026-06-10T05:46:02.056Z", "location_count": 3, "location_summary": "Ann Arbor, Michigan • Rochester, New York • Portland, Oregon", "locations": [ { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Rochester", "state": "New York" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT01663285" }, { "nct_id": "NCT00645593", "title": "Study of Gemcitabine and Cisplatin With or Without Cetuximab in Urothelial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "Gemcitabine,", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 89, "start_date": "2008-03", "completion_date": "2015-06", "has_results": true, "last_update_posted_date": "2016-05-23", "last_synced_at": "2026-06-10T05:46:02.056Z", "location_count": 14, "location_summary": "Duarte, California • Los Angeles, California • Stanford, California + 11 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00645593" }, { "nct_id": "NCT00805129", "title": "Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Cancer", "Metastatic Transitional Cell Carcinoma" ], "interventions": [ { "name": "Everolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2008-12-05", "completion_date": "2021-12-15", "has_results": true, "last_update_posted_date": "2022-11-25", "last_synced_at": "2026-06-10T05:46:02.056Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00805129" }, { "nct_id": "NCT00004203", "title": "Oxaliplatin in Treating Patients With Metastatic Bladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Cancer", "Transitional Cell Cancer of the Renal Pelvis and Ureter" ], "interventions": [ { "name": "oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2000-02", "completion_date": "2005-04", "has_results": false, "last_update_posted_date": "2013-09-05", "last_synced_at": "2026-06-10T05:46:02.056Z", "location_count": 11, "location_summary": "Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 6 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Decatur", "state": "Illinois" }, { "city": "Evanston", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004203" }, { "nct_id": "NCT00045630", "title": "S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Cancer", "Transitional Cell Cancer of the Renal Pelvis and Ureter", "Urethral Cancer" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "gemcitabine", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 77, "start_date": "2003-01", "completion_date": "2011-12", "has_results": true, "last_update_posted_date": "2013-05-27", "last_synced_at": "2026-06-10T05:46:02.056Z", "location_count": 128, "location_summary": "Anchorage, Alaska • Glendale, Arizona • Mesa, Arizona + 89 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00045630" }, { "nct_id": "NCT04724018", "title": "Sacituzumab Govitecan Plus EV in Metastatic UC", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Urothelial Cancer", "Metastatic Urothelial Carcinoma", "Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter", "Bladder Cancer" ], "interventions": [ { "name": "Sacituzumab Govitecan (SG)", "type": "DRUG" }, { "name": "Enfortumab vedotin-ejfv (EV)", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 106, "start_date": "2021-05-20", "completion_date": "2028-05-01", "has_results": false, "last_update_posted_date": "2025-11-04", "last_synced_at": "2026-06-10T05:46:02.056Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04724018" } ] }